DURHAM, N.C., March 28, 2019 /PRNewswire/ -- StrideBio, Inc, a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop in vivo AAV based therapies for Friedreich's Ataxia (FA) and two additional undisclosed targets. These programs aim to utilize novel AAV capsids developed by StrideBio to improve potency, evade neutralizing antibodies and enhance specific tropism to tissues including the central nervous system.

"We are very excited to partner with Takeda given their expertise and commitment to developing treatments for patients with neurological diseases," stated Sapan Shah, Ph.D. Chief Executive Officer, StrideBio, Inc. "We look forward to working together to bring transformative and novel AAV-based gene therapies to patients, while continuing to validate and expand StrideBio's platform, manufacturing capabilities and pipeline."

Read the entire article HERE